SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II
Partnership Or Acquisition On The Cards
The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration.
